Real-World DHT Adherence Insights And Good Practice For Clinical Development

While advances in sensors and device design are improving wearability, successful data collection still hinges on participant adherence—something that can be especially challenging in patient populations affected by fatigue, cognitive issues, skin sensitivities, or fine motor difficulties. This presentation explores how digital health technologies (DHTs) are transforming clinical trials by enabling continuous, remote monitoring of patient function and behavior.

The session highlights why addressing adherence can’t be an afterthought. Experts from Pfizer, Johnson & Johnson, and Novartis share practical insights and lessons learned from deploying DHTs in clinical studies. They explore common barriers to adherence and describe how thoughtful strategies—implemented across study design, participant engagement, and statistical analysis—can maximize data completeness and unlock new insights for drug development.